About VeraMorph
VeraMorph is a pre-clinical strategic pharmaceutical company driven by the mission of prolonging and improving patient lives by maximizing the therapeutic potential of any and all therapeutic drug substances with our oral drug delivery platform. VeraMorph was founded in 2017 by an MIT post-doc with a vision of applying advanced materials and chemical engineering principles to improve human health.
We've since expanded into a lean corporation supported by federal grants and external investors accelerating the development of clinically differentiated drug products that will improve patient outcomes.
Our Team
VeraMorph is led by a passionate team of executives comprising decades of experience with the development, manufacturing, and regulations of pharmaceutical drug products, ensuring the successful and efficient translation of novel formulations into safe and effective therapies. The R&D team is equally driven and experienced with synthesis, formulation, and quality control, working efficiently in a collaborative and fast-paced environment.
.png)
Doug Godfrin is the founder, CEO, and President of VeraMorph. He has a Ph.D. in chemical engineering from the University of Delaware and was formerly a post-doc at MIT. He is the inventor of the DPOD platform technology. Doug has 12 years of experience in pharmaceutical formulation, yielding 16 published papers and 3 patents, and is an accomplished scientific leader, having secured and successfully led multiple SBIR grants. He is also an experienced executive, serving as president and lead scientist at VeraMorph for 6 years and securing roughly $1.4 million in external funding to support VeraMorph. Doug directs both the R&D and leadership teams to align technical and commercialization milestones, which he also sets via business development and customer acquisition.
.png)
Colin Minchom has served as the VP of Manufacturing since 2020 in a part-time capacity. Colin has a Ph.D. in pharmaceutics and has over 30 years of experience in manufacturing and quality control practices, having served as the VP at several pharmaceutical companies and contract manufacturers leading drug product manufacturing sites. Colin also brings experience in preparing regulatory documents (e.g., IND and NDA), having worked on several drug products during his career.
.png)
Ray Forslund has served as the VP of Regulatory since 2022 in a part-time capacity. Ray has a Ph.D. in organic chemistry and an M.B.A. with over 20 years of experience in regulatory strategy and filings. Ray’s experience preparing regulatory documents (e.g., IND and NDA) will be a critical contribution to VeraMorph’s commercialization strategy for DPOD-based products.
Our Company
VeraMorph is a lean specialty pharmaceutical company leveraging internal expertise in materials science, pharmaceutical formulation, and process chemistry to efficiently develop high value, clinically differentiated drug products leveraging our platform oral drug delivery technology, while leveraging the capabilities of commercialization partners to bring those products to market in a cost-effective, accelerated timeline.
Strategy
VeraMorph is creating value through the development of both a portfolio of patent-protected oral drug products and out-licensing of our platform technology to pharmaceutical partners developing novel drug products across several disease areas. This approach diversifies revenue streams in such a way that optimizes the balance of maximizing value creation while minimizing associated regulatory and clinical risk for shareholders.
What we value
Patient-focused product design to maximize quality of life
R&D efficiency to commercialize affordable therapies
Scientific rigor to ensure products of the highest quality
Innovation to improve upon standard of care
A culture of empathy and teamwork to consider all perspectives
Connect with Our Team
.webp)
.avif)
Have a question or need assistance? We're here to help! Reach out to us anytime, and our team will get back to you as soon as possible.
.png)